Physiological Effects of ANGPTL3 Variants in Humans

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
University of Pennsylvania
Study ID
NCT04234724
Status
Recruiting
Apply to this trial

Conditions

  • Hypocholesterolemia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Kinetics test, oral fat tolerance test, and an oral glucose tolerance test. — OTHER
    Subjects will participate in a kinetics test, oral fat tolerance test, and an oral glucose tolerance test.

Study Details

To evaluate the role of ANGPTL3, on lipid metabolism. To explore the role of this protein on glucose metabolism.

Key Dates

Start date
Dec 1, 2020
Status verified
Sep 2025
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
50 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Experimental: Variant
    Volunteers with known ANGPTL3 variants
  • Other: Non-variant
    Healthy volunteers with no ANGPTL3 variants

Primary Outcome Measure

The role of ANGPTL3 on lipid metabolism. [ Time Frame: through study completion, an average of 13 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of PennsylvaniaPhiladelphiaPennsylvania19104
Lauren Vincent, MRA
215-615-5448
Marina Cuchel, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Philadelphia, PA

By research site
University of Pennsylvania· Philadelphia, PA